Investment surges, hurdles and emerging innovations in neuroscience
Innovation in neuropsychiatry has been dormant for nearly forty years, said Kabir Nath, CEO, Compass Pathways in a panel discussion…
All articles by Irena Maragkou
Irena Maragkou
Irena Maragkou is a Healthcare Researcher for Clinical Trials Arena and Pharmaceutical Technology based in London, UK. Irena previously worked in consulting at Deloitte’s Strategy, M&A and Analytics Department, focusing on projects in the Pharmaceutical and Healthcare Sector. She holds an MSci degree in Neuroscience from UCL.
-
-
CPHI Europe: how AI can drive growth in the nutraceutical space
“Consumer demands drive flexible and optimised manufacturing processes and also infrastructure,”said Catarina Abreu, Head of Nutraceuticals at PIPA AI. At…
-
CPHI Europe: strategies to navigate nitrosamines risk evaluation
Drug impurities such as nitrosamines can often contaminate drugs leading to recalls and regulatory actions given their carcinogenic nature. These…
-
Cell and gene therapy approvals drive paradigm change in manufacturing
Innovative cell and gene therapies (CGTs) have significantly disrupted the treatment landscape for several genetic diseases. In recent years, the…
-
CPHI Europe: Targeting supply chain bottlenecks key for cell and gene therapies
Cell therapies stand at the frontier of medicine and hold the potential to potentially cure diseases, said Angela Vollstedt, global…
-
CPHI Europe: Overcoming the unique challenges with high-concentration mAbs
There is an increasing number of high-concentration mAbs among approved therapeutics, with 76% of US Food and Drug Administration (FDA)-approved mAbs…
-
CPHI Europe: Gummies as a drug delivery system could improve compliance
Gummies have become the second best-selling delivery model in all of vitamins, mineral and supplements (VMS) space, said Mitchell Slade,…
-
The course to forging long-term manufacturing partnerships for gene therapies
The current adeno-associated virus (AAV) vector manufacturing landscape in 2024 is a “buyer’s market” with companies competing for clinical trial…
-
ESC 2024: Emerging data on novel therapeutic strategies for targeting lipids
On the third day of the ESC Congress European Society of Cardiology (ESC) Congress (1 September), several discussions centred on…
-
ESC 2024: Obesity drugs emerge as attractive tool for heart failure prevention
Obesity is an independent risk factor for heart failure, said Dr. Carolyn Lam during the opening presentation of the European…